Tandem Diabetes Care, Inc.
Financials
Valuation Metrics
Tandem Diabetes Care, Inc.'s Market Cap is $1.31B. At end of 2025 it was $1.49B. Ranked #2246 of 3,116 in US market (top 72%), #897 of 1,472 on NASDAQ (top 61%), #143 of 203 in Health Care Equipment & Services (top 70%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.31B | US#2,246/3,116 Sec#143/203 |
| Revenue | $1.04B | US#1,843/3,116 Sec#114/203 |
| Net Income | $-63M | US—/3,116 Sec—/203 |
| Total Assets | $1.15B | US#2,401/3,116 Sec#123/203 |
| Net Assets | $130M | US#2,759/3,116 Sec#173/203 |
| Employees | 2,500 | US#1,556/3,116 Sec#110/203 |
| Value | ||
| P/B | 10.04x | US#2,628/3,116 Sec#169/203 |
| P/S | 1.26x | US#907/3,116 Sec#58/203 |
| FCF Yield | -2.03% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -48.56% | US#2,663/3,116 Sec#168/203 |
| ROA | -5.49% | US#2,541/3,116 Sec#143/203 |
| Op. Margin | -4.13% | US#2,433/3,116 Sec#143/203 |
| Revenue Growth | -7.10% | US#2,493/3,116 Sec#187/203 |
| Financial Health | ||
| Debt Ratio | 785.21% | US#2,591/3,116 Sec#188/203 |
| Total Debt | $739M | US#1,678/3,116 Sec#92/203 |
| FCF | $-27M | US#2,449/3,116 Sec#164/203 |
| Cash | $63M | US#2,473/3,116 Sec#155/203 |
| Current Ratio | 3.18x | US#726/3,116 Sec#72/203 |
| Performance | ||
| 1Y Return | 30.95% | US#889/3,116 Sec#77/203 |
| 1M Return | 17.14% | US#242/3,116 Sec#26/203 |
| From 52W High | -35.56% | US#2,146/3,116 Sec#162/203 |
| 1Y MDD | -54.64% | US#2,566/3,116 Sec#161/203 |
| Trading | ||
| Volume | 1,222,261 shares | US#747/3,116 Sec#35/203 |
| Trading Value | $23M | US#1,311/3,116 Sec#99/203 |
| Per Share | ||
| EPS | $-0.92 | US—/3,116 Sec—/203 |
| BPS | $1.90 | US#2,575/3,116 Sec#169/203 |
Company Info
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.